Treatment Efficacy and Safety of Tenofovir-Based Therapy in ChronicHepatitis B: A Real Life Cohort Study in Korea

Collection with item attached
2017
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/486498.do
DOI
10.1371/journal.pone.0170362
Title
Treatment Efficacy and Safety of Tenofovir-Based Therapy in ChronicHepatitis B: A Real Life Cohort Study in Korea
Description
This work was supported by the Catholic Medical Center ResearchFoundation program in 2014, grant number 5-2014-60001-00176, and thefunders had no role in study design, data collection and analysis,decision to publish, or preparation of the manuscript.
abstract
Background & Aims
We evaluated the efficacy and safety of Tenofovir disoproxil fumarate (TDF)-based therapy in naive and treatment-experienced chronic hepatitis B (CHB) patients for 96 weeks in Korean real life practice.
Methods
A total of 209 CHB patients with a prescription for TDF at the Seoul and Daejeon St. Mary's hospitals were enrolled from December 2012 to October 2014. We compared the virological responses and evaluated the renal safety of treatment-naive and treatment-experienced patients.
Results
An overall complete virological response (CVR) was achieved in 80.4% and 84.6% of patients at weeks 48 and 96, respectively. In a subgroup analysis, CVR at week 96 was present in 88.4%, 75.0%, 75.5%, and 83.3% of participants in the lamivudine-resistant (LAM-R) group, adefovir-resistant (ADV-R) group, multidrug-resistant (MDR) group, and suboptimal response group, respectively. In a multivariate analysis, ADV-R, MDR, hepatitis B virus DNA, and hepatitis B e antigen were independent predictors for CVR. With regard to renal safety, diabetes mellitus, cirrhosis, and an initial low estimated glomerular filtration rate were independent factors affecting creatinine elevation (>= 0.5 mg/dL). Moreover, two patients with DM and cirrhosis experienced TDF-related Fanconi syndrome.
Conclusions
TDF-based therapy demonstrated sustained viral suppression and favorable safety during a 2-year treatment period. The LAM-R and suboptimal response groups showed comparable efficacy to the naive group, while the ADV-R and MDR groups were significantly associated with a low CVR. Close monitoring of renal safety should be mandatory when treating CHB patients receiving TDF, particularly those with DM and cirrhosis.
provenance
Made available in Cube on 2018-09-28T16:09:13Z (GMT). No. of bitstreams: 0
language
English
author
Ahn, Hyo Jun
Song, Myeong Jun
Jang, Jeong Won
Bae, Si Hyun
Choi, Jong Young
Yoon, Seung Kew
accessioned
2018-09-28T16:09:13Z
available
2018-09-28T16:09:13Z
issued
2017
citation
PLOS ONE(12): 1
issn
1932-6203
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/486498.do
Funder
교육부
Funding Program
BK21플러스사업(0.5)
Project ID
1345274430
Jurisdiction
Rep.of Korea
Project Name
BK21 PLUS Convergence HealthCare Science Program
rights
openAccess
type
article


Files in This Item

There are no attached files.